Posted in | Nanomedicine | Nanobusiness

Nanosphere Announces Collaboration with Eli Lilly and Company

Nanosphere, Inc. (Nasdaq:NSPH), a leader in the development and commercialization of advanced molecular diagnostics systems, announced today that it has entered into an agreement with Eli Lilly and Company (NYSE:LLY) to collaborate in connection with employing pharmacogenetic assays in drug development initiatives. The two companies have signed the agreement and the financial terms were not disclosed.

Nanosphere is developing the pharmacogenetic assays for use with its new Verigene SP(r) system -- a sample-to-result, bench top molecular diagnostics instrument. The turnkey and random access system uses whole blood and requires no PCR. It allows for broad dissemination to recruitment sites which have no molecular laboratories or to facilities already performing genetic testing.

Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene(r) System, for direct genomic and ultra-sensitive protein detection. This easy to use and cost effective platform enables simple, low cost and highly sensitive genomic and protein testing on a single platform. Nanosphere is based in Northbrook, IL. Additional information is available at

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback